BCYC
Bicycle Therapeutics Plc Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website bicycletherapeutics.com
- Employees(FY) 236
- ISIN US0887861088
Performance
-7.29%
1W
-0.78%
1M
+32.85%
3M
+62.92%
6M
+26.6%
YTD
-2.05%
1Y
Profile
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Investment Analysis Report: BCYC
Overview:
BCYC is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has shown significant growth in its financial metrics over the past three years, with a notable increase in total assets, revenue, and cash flow. In this report, we will analyze BCYC's fi...
Technical Analysis of BCYC 2024-05-03
Overview:
In analyzing the technical indicators for BCYC over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been consistently above the closing prices, ...
Recent News & Updates
- 2024-05-07 07:02
- 2024-05-06 12:00
- 2024-05-06 09:55
- 2024-05-06 00:00
- 2024-05-05 21:55
- 2024-05-04 10:11
Bicycle Therapeutics First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-02 08:44
- 2024-05-02 07:00
- 2024-05-02 01:54
- 2024-05-01 19:00
- 2024-04-24 10:05
- 2024-04-23 22:05
- 2024-04-02 07:00
- 2024-04-01 19:00
- 2024-03-05 16:35
- 2024-03-05 03:35
- 2024-02-28 07:00
- 2024-02-27 18:00
- 2024-02-23 06:51
- 2024-02-21 14:25
- 2024-02-20 07:05
- 2024-02-19 18:05
- 2024-02-07 07:00
- 2024-02-06 18:00
- 2024-01-22 10:54
15 Small-Cap Stocks with High Potential(Insider Monkey)
- 2024-01-05 02:02
Bicycle Therapeutics PLC CEO Kevin Lee Sells 8,703 Shares(GuruFocus.com)
- 2023-12-14 07:00
- 2023-12-13 18:00
- 2023-11-30 07:00
Bicycle Therapeutics to Host R&D Day on December 14(Business Wire)
- 2023-11-29 18:00
Bicycle Therapeutics to Host R&D Day on December 14(businesswire)
Page 1 of 5
previousnext